Novavax Inc.

9.23
0.14 (1.57%)
At close: Jan 24, 2025, 4:14 PM
undefined%
Bid n/a
Market Cap 1.48B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.09
PE Ratio (ttm) -4.42
Forward PE n/a
Analyst n/a
Ask n/a
Volume 2,492
Avg. Volume (20D) 3,404
Open 9.05
Previous Close 9.09
Day's Range 9.03 - 9.23
52-Week Range 3.33 - 23.93
Beta undefined

About NVV1.F

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 1, 2001
Employees 1,543
Stock Exchange XETRA
Ticker Symbol NVV1.F
No News article available yet